Across the entire cohort, neither TP53 nor PTEN correlated with poor survival, but histologic-specific analysis demonstrated that TP53 mutation correlated with decreased survival in ccRCC (p = 0.0002) and PRCC (p = 0.0049), while PTEN mutation correlated with decreased survival in ChRCC (p = 0.0138) (Figures 2A and S2B). Here, TP53 is linked to nonpapillary renal cell carcinoma.